Wipro Healthcare and Life Sciences CEO Sangita Singh, also one of the most respected names in the IT healthcare services business has quit the company. Sangita has ended her 23 yrs of long journey with the company.She was a part of the company's ambition to make healthcare and Lifesciences business reach a $1-billion mark by 2016. Healthcare and life sciences contributed $860 million or 11.4%...
Login or Register to read the full article
Wipro Healthcare and Life Sciences CEO Sangita Singh, also one of the most respected names in the IT healthcare services business has quit the company. Sangita has ended her 23 yrs of long journey with the company.
She was a part of the company's ambition to make healthcare and Lifesciences business reach a $1-billion mark by 2016. Healthcare and life sciences contributed $860 million or 11.4% to the $7.6 billion IT firm's topline
Senior VP Jeffrey Heenan-Jalil, who is currently the global head of Wipro Analytics, will take over as the global head of healthcare & lifesciences strategic business unit, as confirmed by the TOI.
The reasons speculated for the resignations has been put in the context of few top leaders expressing dissatisfaction over not being promoted or elevated in the company. Worryingly for Wipro, three senior executives have left the company since the start of the fiscal year, when the company undertook its biggest management reshuffle in four years, which included the appointment of former Tata Consultancy Services Ltd executive Abidali Neemuchwala as chief operating officer, as reported by the Mint.
Since 2011, Wipro has struggled to grow more than 8% in US dollar terms in a year. In the last twelve months, it has elevated two of its business unit heads and two heads from the delivery side of the business to the rank of president, making some executives who have not have been elevated feel left out.
"Well, clearly, there seems to be some discontent among executives who believe they should have been promoted but have not been," said the head of an executive search firm.
Wipro has clearly dismissed any talk of dissatisfaction.
She was a part of the company's ambition to make healthcare and Lifesciences business reach a $1-billion mark by 2016. Healthcare and life sciences contributed $860 million or 11.4% to the $7.6 billion IT firm's topline
Senior VP Jeffrey Heenan-Jalil, who is currently the global head of Wipro Analytics, will take over as the global head of healthcare & lifesciences strategic business unit, as confirmed by the TOI.
The reasons speculated for the resignations has been put in the context of few top leaders expressing dissatisfaction over not being promoted or elevated in the company. Worryingly for Wipro, three senior executives have left the company since the start of the fiscal year, when the company undertook its biggest management reshuffle in four years, which included the appointment of former Tata Consultancy Services Ltd executive Abidali Neemuchwala as chief operating officer, as reported by the Mint.
Since 2011, Wipro has struggled to grow more than 8% in US dollar terms in a year. In the last twelve months, it has elevated two of its business unit heads and two heads from the delivery side of the business to the rank of president, making some executives who have not have been elevated feel left out.
"Well, clearly, there seems to be some discontent among executives who believe they should have been promoted but have not been," said the head of an executive search firm.
Wipro has clearly dismissed any talk of dissatisfaction.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd